



Not all Pap tests are created equal.

The BD SurePath™ Liquid-based Pap Test offers a simple method to collect cervical samples and send 100% of the cells to the laboratory. Just drop and send. No need to swish, swirl or count.



Easier collection. Lower unsats. Higher confidence.


✓ Assurance that you'll simplify collection

Collecting a cervical sample has never been easier.

SIMPLE 3-STEP PROCESS



1. Collect



2. Drop




3. Send

✓ Assurance that you'll have fewer unsatisfactory results^{1,2}

Only the BD SurePath™ Liquid-based Pap Test has proven to consistently lower the unsat rate,^{3,4} due to its proprietary cell-enrichment process.^{1,5,6}

Blood is a primary symptom of a patient with cervical cancer.⁴ As little as 50 µL of blood can compromise the ThinPrep® test, with epithelial cell counts dropping to near zero.⁶

**CELLULARITY
RETAINED WITH
50µL BLOOD ADDED**



The BD SurePath™ Liquid-based Pap Test removes debris such as blood, mucus and inflammatory cells, aiding in visualization of diagnostically relevant cells—and reducing patient callbacks.^{1,6}




✓ Assurance that you'll have actionable results for patient management

Only the BD SurePath™ Liquid-based Pap Test provides:

- Low unsat rates,^{1,3–5} reducing patient callbacks
- Low ASCUS rates,⁷ minimizing additional tests
- A **64.4%** increase in HSIL+ detection over conventional Pap^{2,8}
- Identification of more precursor lesions, leading to fewer cases of cervical cancer in the follow-up period⁹

For actionable results, be sure with the BD SurePath™ Liquid-based Pap Test.



BD is your only trusted partner for the BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay—both approved by the FDA—for HPV primary screening, co-testing and cytology primary with ASCUS reflex.

**Change today for total
assurance tomorrow.
Be sure with BD SurePath.™**

References: 1. Moriarty A et al. *Arch Pathol Lab Med.* 2009;133(12):1912–1916. 2. BD PrepStain™ System Product Insert 500017014. 3. Sass MA. *Acta Cytol.* 2004;48(1):17–22. 4. Fontaine D et al. *BMJ Open.* 2012; doi:10.1136/bmjopen-2012-000847. 5. Marino J et al. *J Reprod Med.* 2001;46(4):353–358. 6. Sweeney B et al. *Cancer.* 2006;108(1):27–31. 7. Fremont-Smith M et al. *Cancer Cytopathol.* 2004;102(5):269–279. 8. Nance KV. *Diagn Cytopathol.* 2007;35(3):148–153. 9. Rozemeijer K et al. *BMJ.* 2017;356(j504):1–9.

BD, 7 Loveton Circle, Sparks, MD 21152-0999 USA
Tel: 1.800.638.8663

bd.com

BD, the BD Logo and BD SurePath are trademarks of Becton, Dickinson and Company or its affiliates.
All other trademarks are the property of their respective owners. © 2019 BD. All rights reserved. 223505-US

